Accessibility Menu
Helix BioPharma logo

Helix BioPharma

(OTC) HBPCF

Current Price$1.71
Market Cap$130.61M
Since IPO (2010)-87%
5 Year-55%
1 Year+190%
1 Month-1%

Helix BioPharma Financials at a Glance

Market Cap

$130.61M

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$4.25M

EPS (TTM)

-$0.05

P/E Ratio

-37.25

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$1.71

Volume

1,000

Open

$1.71

Previous Close

$1.71

Daily Range

$1.71 - $1.71

52-Week Range

$0.60 - $1.73

HBPCF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Helix BioPharma

Industry

Biotechnology

Employees

7

CEO

Thomas Mehrling, MD, PhD

Headquarters

Toronto, ON M5H 2Y4, CA

HBPCF Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-53%

Return on Capital

-27%

Return on Assets

-23%

Earnings Yield

-2.68%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$130.61M

Shares Outstanding

76.38M

Volume

1.00K

Avg. Volume

22.131

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$5.00M

EBITDA

-CA$5.00M

Operating Cash Flow

-CA$4.00M

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$4.00M

Cash & ST Invst.

CA$64.64K

Total Debt

CA$333.15K

Helix BioPharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$1.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$130.61M

N/A

Market Cap/Employee

$18.66M

N/A

Employees

7

N/A

Net Income

-CA$695.09K

+49.4%

EBITDA

-CA$682.07K

+50.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Net Cash

-CA$328.52K

-116.5%

Accounts Receivable

CA$25.04K

-89.4%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$359.57K

N/A

Return on Assets

-22.65%

N/A

Return on Invested Capital

-27.11%

N/A

Free Cash Flow

-CA$456.72K

+51.5%

Operating Cash Flow

-CA$456.72K

+51.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INNMFAmplia Therapeutics Limited
$0.10-3.92%
VICPVicapsys Life Sciences, Inc.
$1.46+0.00%
OTLCOncotelic Therapeutics, Inc.
$0.06+3.40%
ACHFFArch Biopartners Inc.
$0.32+0.92%

Trending Stocks

Symbol / CompanyPricePrice Chg
CZRCaesars Entertainment
$29.07+0.01%
IUSBiShares Trust - iShares Core Universal Usd Bond ETF
$46.19+0.00%
FFord Motor Company
$16.48+0.04%
RCATRed Cat
$14.18+0.33%

Questions About HBPCF

What is the current price of Helix BioPharma?

Helix BioPharma is trading at $1.71 per share.

What is the 52-week range for Helix BioPharma?

Over the past 52 weeks, Helix BioPharma has traded between $0.60 and $1.73.

How much debt does Helix BioPharma have?

As of the most recent reporting period, Helix BioPharma reported total debt of CA$265.11K.

How much cash does Helix BioPharma have on hand?

Helix BioPharma reported CA$22.89K in cash and cash equivalents in its most recent financial results.

What is Helix BioPharma’s dividend yield?

Helix BioPharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.